ulotaront

Also known as SEP-363856

Ulotaront (; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals (which was subsequently merged into Sumitomo Pharma) using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube.

In the Vinony graph

Within Vinony's link graph, ulotaront is referenced by 139 other articles, and connects out to schizophrenia, agonist and TAAR1.

It is catalogued under topics including 5-HT1A agonists, 5-HT1D agonists and Antipsychotics.

Its subject is documented across 5 Wikipedia language editions.

Chemical data

Formula: C9H13NOS
Molecular weight: 183.27 g/mol
IUPAC name: 1-[(7S)-5,7-dihydro-4H-thieno[2,3-c]pyran-7-yl]-N-methylmethanamine
SMILES: CNC[C@H]1C2=C(CCO1)C=CS2
InChIKey: ABDDQTDRAHXHOC-QMMMGPOBSA-N
XLogP: 0.9
Polar surface area: 49.5 Å²
H-bond donors: 1
H-bond acceptors: 3
Formal charge: 0

via PubChem

Wikidata facts

Subclass of: chemical compound
Mass: 183.071785036

Show 4 more facts

Commons category: Ulotaront
isomeric SMILES: CNC[C@@H]1OCCc2ccsc21
canonical SMILES: CNCC1OCCc2ccsc21
chemical formula: C₉H₁₃NOS

via Wikidata · CC0

~4 min read

Encyclopedic overview

7 sections

Contents

Adverse effects
Pharmacology
Pharmacodynamics
Pharmacokinetics
Research
See also
References

Ulotaront is in phase III clinical trial for schizophrenia, phase II/III for generalized anxiety disorder and major depressive disorder, and discontinued for narcolepsy and psychotic disorders.

Excerpted from Wikipedia’s “ulotaront” article, available under the CC BY-SA 4.0 licence.